NeuBase Therapeutics Inc (NAS:NBSE)
$ 0.378 -0.012499 (-3.2%) Market Cap: 1.42 Mil Enterprise Value: -5.82 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 20/100

NeuBase Therapeutics Inc at Chardan Genetic Medicines Conference Transcript

Oct 3, 2022 / 01:00 PM GMT
Release Date Price: $7.92 (+0.25%)


Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

NBSE.OQ - NeuBase Therapeutics Inc
NeuBase Therapeutics Inc at Chardan Genetic Medicines Conference
Oct 03, 2022 / 01:00PM GMT

=====================
Corporate Participants
=====================
* Dietrich Stephan
NeuBase Therapeutics, Inc. - CEO, Founder & Director
* Todd Branning
NeuBase Therapeutics, Inc. - CFO

=====================
Questions and Answers
--------------------------------------------------------------------------------
Unidentified Analyst [1]
--------------------------------------------------------------------------------
It's my pleasure to introduce our next guest from NeuBase Therapeutics, Chairman and CEO, Dietrich Stephan; and CFO, Todd Branning. Thank you for joining us today. This is going to be a fireside chat. And Dietrich, to start, could you provide a brief overview of the company for those who are new to the story?

--------------------------------------------------------------------------------
Dietrich Stephan, NeuBase Therapeutics, Inc. - CEO,
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot